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General chemistry methods
All air or moisture sensitive reactions were performed under positive pressure of nitrogen with oven-dried glassware. Anhydrous solvents such as dichloromethane, N,Ndimethylformamide (DMF), acetonitrile, methanol and triethylamine were purchased from Sigma-Aldrich (St. Louis, MO). Preparative purification was performed on a Waters semi-preparative HPLC system (Waters Corp., Milford, MA) . The column used was a Phenomenex Luna C 18 (5 micron, 30 x 75 mm; Phenomenex, Inc., Torrance, CA) at a flow rate of 45.0 mL/min. The mobile phase consisted of acetonitrile and water (each containing 0.1% trifluoroacetic acid). A gradient of 10% to 50% acetonitrile over 8 min was used during the purification. Fraction collection was triggered by UV detection at 220 nM. Analytical analysis was performed on an Agilent LC/MS (Agilent Technologies, Santa Clara, CA). Method 1: A 7-min gradient of 4% to 100% acetonitrile (containing 0.025% trifluoroacetic acid) in water (containing 0.05% trifluoroacetic acid) was used with an 8-min run time at a flow rate of 1.0 mL/min. Method 2: A 3-min gradient of 4% to 100% acetonitrile (containing 0.025% trifluoroacetic acid) in water (containing 0.05% trifluoroacetic acid) was used with a 4.5-min run time at a flow rate of 1.0 mL/min. A Phenomenex Luna C 18 column (3 micron, 3 x 75 mm) was used at a temperature of 50 °C. Purity determination was performed using an Agilent diode array detector for both Method 1 and Method 2. Mass determination was performed using an Agilent 6130 mass spectrometer with electrospray ionization in the positive mode. 1 H NMR spectra were recorded on Varian 400 MHz spectrometers (Agilent Technologies, Santa Clara, CA). Chemical shifts are reported in ppm with undeuterated solvent (DMSO at 2.49 ppm) as internal standard for DMSO-d 6 solutions. All of the analogs tested in the biological assays have a purity of greater than 95% based on both analytical methods. High resolution mass spectrometry was recorded on Agilent 6210 Time-of-Flight (TOF) LC/MS system. Confirmation of molecular formula was accomplished using electrospray ionization in the positive mode with the Agilent Masshunter software (Version B.02).
General Protocol A. A mixture of acid (0.095 mmol, 1.0 equiv.) and amine (0.19 mmol, 2 equiv.) in DMF (1.00 mL) was treated at room temperature with EDC (0.19 mmol, 2.0 equiv.) and DMAP (0.19 mmol, 2.0 equiv.). The reaction mixture was stirred at room temperature overnight. The crude material was purified by preparative HPLC to give the final product.
General Protocol B. A solution of acid (0.16 mmol, 1.0 equiv.) in DMF (2.00 mL) was treated at room temperature with HATU (0.32 mmol, 2.0 equiv.) and DIPEA (0.32 mmol, 2.0 equiv.). The mixture was stirred at room temperature for 5 min, and then amine (0.32 mmol, 2.0 equiv.) was added. The reaction mixture was stirred at room temperature overnight. The crude material was purified by preparative HPLC to give the final product.
Synthetic methods and compound characterization
Methyl 4-(2-(methoxycarbonyl)phenylthio)- 3-nitrobenzoate (4) . A solution of methyl 4fluoro-3-nitrobenzoate (12.1 g, 60.9 mmol) and methyl 2-mercaptobenzoate (9.21 mL, 66.9 mmol) in DMF (6.00 mL) was treated with Cs 2 CO 3 (19.8 g, 60. 9 mmol) at room temperature. The reaction mixture was stirred at 40 °C for 4 h and then cooled to room temperature. Ice water was added to induce the precipitation. The precipitate was filtered, washed with water, and dried to give 21.0 g (99%) of the title compound as a yellow solid which was used directly in the next reaction without further purification. 1 4-(2-Carboxyphenylthio)- 3-nitrobenzoic acid (5) . A solution of methyl 4-(2-(methoxycarbonyl)phenylthio)-3-nitrobenzoate (21.0 g, 60.5 mmol) in THF (150 mL) and water (150 mL) was treated at room temperature with LiOH (14.5 g, 605 mmol). The reaction mixture was stirred at 60 °C for 2 h. The organic solvent was removed and the aqueous solution was washed with EtOAc and acidified with 2 N HCl until pH = ~2. The yellow precipitate was filtered, washed with water, and dried to give 19.1 g (99%) of the title compound as a yellow solid which was used directly in the next reaction without further purification. 1 3-Amino-4-(2-carboxyphenylthio)benzoic acid (6) . A solution of 4-(2carboxyphenylthio)-3-nitrobenzoic acid (8.70 g, 27.2 mmol) in MeOH (300 mL) was treated at room temperature with platinum (IV) oxide (300 mg, 1.32 mmol) and 10% Pd/C (600 mg, 5.64 mmol). A balloon containing H 2 was connected to the flask and the reaction flask was repeatedly evacuated and refilled with H 2 . After 16 h, additional Pd/C (10%, 600 mg, 5.64 mmol) was added and the reaction mixture was stirred under H 2 balloon for an additional 32 h. The reaction mixture was filtered through a pad of celite and concentrated to give 7.80 g (99%) of the title compound as a grey-yellow solid which was used directly in the next reaction without further purification. 1 f] [1, 4] thiazepine-8-carboxylic acid (7) . A solution of 3-amino-4-(2-carboxyphenylthio)benzoic acid (4.76 g, 16.5 mmol) in THF (100 mL) was treated at 0 °C with 1,1'-carbonyldiimidazole (CDI) (10.7 g, 65.8 mmol) via several portions. The reaction mixture was warmed to room temperature and stirred at room temperature overnight. The reaction mixture was poured into 140 mL of ice water containing concentrated HCl (20.0 mL) and stirred for 1 h. The white precipitate was filtered, washed with water, and dried to give 3.89 g (87%) of the title compound as a white solid which was used directly in the next reaction without further purification. 1 -methyl-11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxylate (8b) . A solution of 11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxylic acid (200 mg, 0.74 mmol) in DMF (5.00 mL) was treated at 0 °C with NaH (295 mg, 7.37 mmol). The reaction mixture was warmed to room temperature and stirred at room temperature for 1 h. Then, a solution of methyl iodide (0.46 mL, 7.37 mmol) in DMF (2.00 mL) was added dropwise to the mixture. The reaction mixture was stirred at room temperature for 1.5 h. Water was carefully added and the aqueous layer was washed with EtOAc. The aqueous layer was acidified with HCl to induce the precipitation which was filtered, washed, and dried to give 200 mg (91%) of the title compound as a yellow solid which was used directly in the next reaction without further purification. 1 f] [1,4]thiazepine-8-carboxylic acid (9b) . A solution of methyl 10-methyl-11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8carboxylate (150 mg, 0.50 mmol) in THF (3.00 mL), MeOH (1.50 mL) and water (0.50 mL) was treated at room temperature with LiOH (120 mg, 5.01 mmol). The reaction mixture was stirred at room temperature for 1 h, diluted with water, and acidified with HCl. The aqueous mixture was extracted with 20% of MeOH in dichloromethane. The organic layer was separated, dried and concentrated to give 140 mg (98%) of the title compound as a grey solid which was used directly in the next reaction without further purification. 1 f] [1,4]thiazepine-8-carboxylic acid 5-oxide (10b) . A suspension of 10-methyl-11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8carboxylic acid (660 mg, 2.31 mmol) in acetic acid (18.8 mL) was treated at room temperature with H 2 O 2 (5.91 mL, 30%, 57.8 mmol) for 8 h. Upon completion, the reaction mixture was poured into a cold saturated solution of Na 2 S 2 O 3 in water and stirred at room temperature for 3 h. The mixture was then extracted with 20% of MeOH in dichloromethane. The organic layer was separated, dried, and concentrated to give 595 mg (85%) of the title compound as a white solid containing ~ 5% of dioxide as a byproduct. 1 f] [1,4]thiazepine-8-carboxylic acid (9c) . A solution of 11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxylic acid (1.50 g, 5.53 mmol) in DMF (30.0 mL) was treated at 0 °C with NaH (2.21 g, 55.3 mmol). The reaction mixture was warmed to room temperature and stirred at room temperature for 1 h. Then a solution of ethyl iodide (4.47 mL, 55.3 mmol) in DMF (12.0 mL) was added dropwisely to the mixture. The reaction mixture was stirred at room temperature for 1.5 h. Water was carefully added and the aqueous layer was washed with EtOAc. The aqueous layer was acidified with HCl to induce the precipitation which was filtered, washed and dried to give 1.46 g (88%) of the title compound as a yellow solid which can be used directly in the next reaction without further purification. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 13.31 (br. s., 1 H), 8.00 (d, J=1.6 Hz, 1 H), 2 H), 1 H), 1 H), 2 H), 4.50 (dq, J=14.0, 7. -ethyl-11-oxo-10,11-dihydrodibenzo[b,f] [1,4]thiazepine-8-carboxylate (8c) . The title compound was isolated as the by-product of 10-ethyl-11-oxo-10,11dihydrodibenzo[b,f] f] [1,4]thiazepine-8-carboxylic acid 5-oxide (10c) . A suspension of 10-ethyl-11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8carboxylic acid (1.00 g, 3.34 mmol) in acetic acid (90.0 mL) was treated at room temperature with H 2 O 2 (14.1 mL, 30%, 138 mmol). The reaction mixture was stirred at room temperature for 8 h. Upon completion, the reaction mixture was poured into a cold saturated solution of Na 2 S 2 O 3 in water and stirred at room temperature for 3 h. The mixture was then extracted with 20% of MeOH in dichloromethane. The organic layer was separated, dried, and concentrated to give 1.00 g (95%) of the title compound as a white solid containing ~ 5% of dioxide as a by-product. 1 f] [1,4]thiazepine-8-carboxylic acid 5,5dioxide (11) . The title compound was isolated as the by-product of 10-ethyl-11-oxo-10,11-dihydrodibenzo[b,f] f] [1,4]thiazepine-8-carboxylic acid (9d) . A solution of 11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxylic acid (200 mg, 0.74 mmol) in DMF (5.00 mL) was treated at 0 °C with NaH (295 mg, 7.37 mmol). The reaction mixture was warmed to room temperature and stirred at room temperature for 1 h. Then a solution of 1-iodopropane (0.72 mL, 7.37 mmol) in DMF (2.00 mL) was added dropwisely to the mixture. The reaction mixture was stirred at room temperature for 1.5 h. Water was carefully added and the reaction mixture was acidified with HCl until pH ~ 3. The solution was extracted with 20% of MeOH in dichloromethane. The organic layer was separated, dried, and concentrated to give 220 mg (95%) of the title compound as a yellow foam which can be used directly in the next reaction without further purification. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 13.29 (br. s., 1 H), 8.00 (d, J=1.6 Hz, 1 H), 7.73 -7.78 (m, 1 H), 7. 66 -7.72 (m, 1 H), 7.55 -7.65 (m, 1 H), 7.44 -7.52 (m, 1 H), 7.32 -7.43 (m, 2 H), 4.55 (dt, J=13.7, 7.4 Hz, 1 H), 3.61 (ddd, J=13.6, 7.9, 5. f] [1, 4] thiazepine-8-carboxylic acid 5-oxide (10d). A suspension of 11-oxo-10-propyl-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8carboxylic acid (115 mg, 0.37 mmol) in acetic acid (3.00 mL) was treated at room temperature with H 2 O 2 (0.94 mL, 30%, 9.20 mmol). The reaction mixture was stirred at room temperature for 8 h. Upon completion, the reaction mixture was poured into a cold saturated solution of Na 2 S 2 O 3 in water and stirred at room temperature for 3 h. The mixture was then extracted with 20% of MeOH in dichloromethane. The organic layer was separated, dried, and concentrated to give 115 mg (95%) of the title compound as a white solid which was used directly in the next reaction without further purification. 1 f] [1,4]thiazepine-8-carboxylate (8e) . A solution of 11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxylic acid (200 mg, 0.74 mmol) in DMF (5.00 mL) was treated at 0 °C with NaH (295 mg, 7.37 mmol). The reaction mixture was warmed to room temperature and stirred at room temperature for 1 h. Then a solution of benzyl bromide (0.88 mL, 7.37 mmol) in DMF (2.00 mL) was added dropwisely to the mixture. The reaction mixture was stirred at room temperature for 1.5 h. Water was carefully added and the reaction mixture was acidified with HCl until pH ~ 3. The solution was extracted with 20% of MeOH in dichloromethane. The organic layer was separated, dried, concentrated and purified on SiO 2 with 0-50% EtOAc in hexanes to give 190 mg (57%) of the title compound as a yellow foam. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 8.06 (d, J=2.0 Hz, 1 H), 7. 60 -7.78 (m, 3 H), 7.46 -7.53 (m, 1 H), 7.38 -7.46 (m, 2 H), 7.28 -7.38 (m, 7 H), 7.22 -7.28 (m, 2 H), 7.13 -7.22 f] [1,4]thiazepine-8-carboxylic acid (9e) . A solution of methyl benzyl 10-benzyl-11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8carboxylate (100 mg, 0.22 mmol) in THF (3.00 mL), MeOH (1.50 mL) and water (0.50 mL) was treated at room temperature with LiOH (53.0 mg, 2.22 mmol). The reaction mixture was stirred at room temperature for 3 h, diluted with water, and acidified with HCl. The aqueous mixture was extracted with 20% of MeOH in dichloromethane. The organic layer was separated, dried and concentrated to give 79.0 mg (99%) of the title compound as a grey solid which can be used directly in the next reaction without further purification. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 13.23 (br. s., 1 H), 8.03 (d, J=1.6 Hz, 1 H), 3 H), 1 H), 2 H), 4 H), 1 H), 5.65 (d, J=15. f] [1, 4] thiazepine-8-carboxylic acid 5-oxide (10e). A suspension of 10-benzyl-11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8carboxylic acid (70.0 mg, 0.19 mmol) in acetic acid (3.00 mL) was treated at room temperature with H 2 O 2 (0.50 mL, 30%, 4.84 mmol) for overnight. Upon completion, the reaction mixture was poured into ice water to induce the precipitation. The precipitation was filtered and washed with water to give 50.0 mg (68%) of the title compound as a white solid which was used directly in the next reaction without further purification. 1 -10-ethyldibenzo[b,f] [1, 4] thiazepin-11(10H)-one 5-oxide (12) . A mixture of 10-ethyl-11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxylic acid 5-oxide (10c, 73.0 mg, 0.23 mmol), diphenylphosphinyl azide (67.6 mg, 0.28 mmol), TEA (0.048 mL, 0.35 mmol) in dioxane (1.25 mL) was stirred at room temperature for 1 h. Water (1.04 mL, 57.9 mmol) was then added to the solution and the reaction mixture was heated at 80 °C for 4 h. The crude material was partitioned between EtOAc and saturated aqueous NaHCO 3 solution. The organic layer was washed with saturated brine, dried over MgSO 4 , and concentrated under reduced pressure to give the crude title compound as a off-white foam which was used directly in the next reaction without further purification. f] [1, 4] f] [1, 4] N-(4-tert-Butylbenzyl)- 10-ethyl-11-oxo-10,11-dihydrodibenzo[b,f] [1, 4] f] [1, 4] f] [1, 4] N-(4-Chlorobenzyl)- 10-ethyl-11-oxo-10,11-dihydrodibenzo[b,f] [1, 4] N-(4-Cyanobenzyl)- 10-ethyl-11-oxo-10,11-dihydrodibenzo[b,f] [1, 4] 4, f] [1, 4] -ethyl-11-oxo-10,11dihydrodibenzo[b,f] [1, 4] -11-oxo-N-phenyl-10,11-dihydrodibenzo[b,f] [1, 4] f] [1, 4] f] [1, 4] N-(4-Methoxybenzyl)- 10-methyl-11-oxo-10,11-dihydrodibenzo[b,f] [1, 4] f] [1, 4] -11-oxo-N-phenyl-10,11-dihydrodibenzo[b,f] [1, 4] f] [1, 4] f] [1, 4] N-(4-Fluorobenzyl)- 10-methyl-11-oxo-10,11-dihydrodibenzo[b,f] [1, 4] f] [1, 4] N- f] [1, 4] -11-oxo-N-(pyridin-2-ylmethyl)-10,11-dihydrodibenzo[b,f] [1, 4] -11-oxo-N-(pyridin-3-ylmethyl)-10,11-dihydrodibenzo[b,f] [1, 4] 11dihydrodibenzo[b, f] [1, 4] -11-oxo-N-(2-(piperidin-1-yl)ethyl)-10,11dihydrodibenzo[b,f] [1, 4] N- propyl)- 10-methyl-11-oxo-10,11dihydrodibenzo[b,f] [1, 4] N-(4-Methoxybenzyl)- 11-oxo-10,11-dihydrodibenzo[b,f] [1,4]thiazepine-8-carboxamide 5,5-dioxide (49) . A solution of 10-ethyl-N-(4-methoxybenzyl)-11-oxo-10,11dihydrodibenzo[b,f][1,4]thiazepine-8-carboxamide (10.0 mg, 0.024 mmol) in dichloromethane (3.00 mL) and was treated at room temperature with MCPBA (53.6 mg, 0.24 mmol). The reaction was stirred at room temperature for overnight. The reaction mixture was washed with saturated Na 2 S 2 O 3 solution. The organic layer was separated, dried and concentrated. The crude mixture was purified by preparative HPLC to give 2.0 mg (19%) of the title compound as a white foam.
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Or the title compound can be prepared through the coupling of 10-Ethyl-11-oxo-10,11dihydrodibenzo f] [1, 4] thiazepine-8carboxamide 5-(S)-oxide ((S)-1). Separation of enantiomers via chiral HPLC: Analytical analysis was performed on a CHIRALPAK ® IA ® column (4.6 × 150 mm, 5 micron). The mobile phase was 60% of isopropanol in hexanes at a flow rate of 1.0 mL/min with a run time of 15 minutes. The sample was detected with a diode array detector (DAD) at 220 nm and 254 nm. Optical rotation was determined with an in-line polarimeter (PDR-Chiral). The first eluting peak: RT = 5.22 minutes; positive optical rotation. The second eluting peak: RT = 5.61 minutes; negative optical rotation. Preparative separation was performed on a CHIRALPAK ® IA ® column (5× 50 cm, 20 micron). The mobile phase was 60% of isopropanol in hexanes at a flow rate of 30 mL/min. Fraction collection was triggered by UV absorbance (254 nm N-(4-Methoxybenzyl)-9,10-dioxo-9,10-dihydroanthracene-2-carboxamide (50). A solution of 9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid (1.00 g, 3.96 mmol) in DMF (15.0 mL) was treated at room temperature with (4-methoxyphenyl)methanamine (1.09 g, 7.93 mmol), HATU (2.26 g, 5.95 mmol) and DIPEA (2.08 mL, 11.9 mmol). The reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated and purified by Biotage with 0-20% of MeOH in CH 2 Cl 2 to give 1.30 g (88%) of the title compound as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ -methyl-11-oxo-10,11dihydrodibenzo[b,f] [1, 4] thiazepine-8-carboxamide 5-oxide (52) . A solution of 10-ethyl-N-(4-methoxybenzyl)-11-oxo-10, 11-dihydrodibenzo[b,f] [1, 4] thiazepine-8-carboxamide in DMF (2.50 mL) was treated at 0 °C with NaH (18.4 mg, 0.46 mmol). The reaction mixture was warmed to room temperature and stirred at room temperature for 1 h. a solution of MeI (0.029 mL, 0.46 mmol) in DMF (1.00 mL) was added to the mixture dropwisely. The reaction mixture was stirred at room temperature for 1.5 h. Water was carefully added and the aqueous layer was extracted with 20% MeOH in dichloromethane. The aqueous layer was separated, dried, concentrated and purified by preparative HPLC to give 12. f] [1, 4] f][1, 4] thiazepine-8carboxylate 5-oxide (54) . A solution of 10-ethyl-11-oxo-10,11dihydrodibenzo[b,f][1,4]thiazepine-8-carboxylic acid 5-oxide (180 mg, 0.57 mmol) in DMF (5.00 mL) and was treated at 0 °C with NaH (68.5 mg, 1.71 mmol). The reaction mixture was warmed to room temperature and stirred at room temperature for 1 h. A solution of 1-(bromomethyl)-4-methoxybenzene (344 mg, 1.71 mmol) in DMF (2.00 mL) was added dropwisely to the mixture. The reaction mixture was stirred at room temperature for 1.5 h. Water was carefully added and the aqueous layer was extracted with EtOAc. The organic layer was separated, dried, concentrated and purified by preparative HPLC to give 21.6 mg (9%) of the title compound. The title compound also can be prepared using a different protocol: A solution of 10-ethyl-11-oxo-10,11dihydrodibenzo[b,f][1,4]thiazepine-8-carboxylic acid 5-oxide (50.0 mg, 0.16 mmol) in DMF (2.00 mL) was treated at room temperature with K 2 CO 3 (110 mg, 0.79 mmol) and 1-(bromomethyl)-4-methoxybenzene (96.0 mg, 0.48 mmol). The reaction mixture was stirred at room temperature overnight. The reaction mixture was filtered and purified by preparative HPLC to give 7.2 mg (10%) of the title compound f] [1, 4] f] [1, 4] thiazepine-8carboxamide 5-(R)-oxide ((R)-58) . Separation of enantiomers via chiral HPLC: Analytical analysis was performed on a CHIRALAPK ® AS column (4.6 × 250 mm, 5 micron). The mobile phase was 100% of methanol at a flow rate of 1.0 mL/min with a run time of 15 minutes. The sample was detected with a diode array detector (DAD) at 220 nm and 254 nm. Optical rotation was determined with an in-line polarimeter (PDR-Chiral). The first eluting peak: RT = 5.95 minutes; positive optical rotation. The second eluting peak: RT = 9.08 minutes; negative optical rotation. Preparative separation was performed on a CHIRALPAK ® AS column (5× 50 cm, 20 micron). The mobile phase was 100% of methanol at a flow rate of 35 mL/min. Fraction collection was triggered by UV absorbance (254 nm N-(4-Cyanobenzyl)- 10-ethyl-11-oxo-10,11-dihydrodibenzo[b,f] [1, 4] N-(1-(4-Bromophenyl) ethyl)- 10-ethyl-11-oxo-10,11dihydrodibenzo[b,f] [1, 4] thiazepine-8-carboxamide 5-(R)-oxide ((R)-59). Separation of enantiomers via chiral HPLC: Analytical analysis was performed on a CHIRALPAK ® IA column (4.6 × 250 mm, 5 micron). The mobile phase was 60% of ethanol in hexanes at a flow rate of 1.0 mL/min with a run time of 15 minutes. The sample was detected with a diode array detector (DAD) at 220 nm and 254 nm. Optical rotation was determined with an in-line polarimeter (PDR-Chiral). The first eluting peak: RT = 5.36 minutes; positive optical rotation. The second eluting peak: RT = 6.44 minutes; negative optical rotation. Preparative separation was performed on a CHIRALPAK ® IA column (5× 50 cm, 20 micron). The mobile phase was 60% of ethanol in hexanes at a flow rate of 35 mL/min. N-(1-(4-Bromophenyl)ethyl)-10-ethyl-11-oxo-10,11 (R)-10-Ethyl-N- (1-(naphthalen-2-yl)ethyl)-11-oxo-10,11dihydrodibenzo[b,f] [1, 4] thiazepine-8-carboxamide 5-(R)-oxide ((R)-60). Separation of enantiomers via chiral HPLC: Analytical analysis was performed on a CHIRALPAK ® IA column (4.6 × 250 mm, 5 micron). The mobile phase was 60% of ethanol in hexanes at a flow rate of 1.0 mL/min with a run time of 15 minutes. The sample was detected with a diode array detector (DAD) at 220 nm and 254 nm. Optical rotation was determined with an in-line polarimeter (PDR-Chiral). The first eluting peak: RT = 5.84 minutes; positive optical rotation. The second eluting peak: RT = 7.19 minutes; negative optical rotation. Preparative separation was performed on a CHIRALPAK ® IA column (5× 50 cm, 20 micron). The mobile phase was 60% of ethanol in hexanes at a flow rate of 35 mL/min. Fraction collection was triggered by UV absorbance (254 nm (R)-10-Ethyl-N- (1-(naphthalen-2-yl)ethyl)-11-oxo-10,11dihydrodibenzo[b,f] [1, 4] f] [1, 4] thiazepine-8carboxamide 5-(R)-oxide ((R)-61). Separation of enantiomers via chiral HPLC: Analytical analysis was performed on a CHIRALPAK ® IA column (4.6 × 150 mm, 5 micron). The mobile phase was 60% of isopropanol in hexanes at a flow rate of 1.0 mL/min with a run time of 15 minutes. The sample was detected with a diode array detector (DAD) at 220 nm and 254 nm. Optical rotation was determined with an in-line polarimeter (PDR-Chiral). The first eluting peak: RT = 5.96 minutes; positive optical rotation. The second eluting peak: RT = 6.72 minutes; negative optical rotation. Preparative separation was performed on a CHIRALPAK ® IA column (5× 50 cm, 20 micron). The mobile phase was 60% of isopropanol in hexanes at a flow rate of 30 mL/min. Fraction collection was triggered by UV absorbance (254 nm f] [1, 4] -methyl-11-oxo-10,11-dihydrodibenzo[b,f] [1, 4] thiazepine-8carboxamide 5-(R)-oxide ((R)-62). Separation of enantiomers via chiral HPLC: Analytical analysis was performed on a CHIRALPAK ® IA column (4.6 × 250 mm, 5 micron). The mobile phase was 60% of ethanol in hexanes at a flow rate of 1.0 mL/min with a run time of 15 minutes. The sample was detected with a diode array detector (DAD) at 220 nm and 254 nm. Optical rotation was determined with an in-line polarimeter (PDR-Chiral). The first eluting peak: RT = 7.49 minutes; positive optical rotation. The second eluting peak: RT = 8.68 minutes; negative optical rotation. Preparative separation was performed on a CHIRALPAK ® IA column (5× 50 cm, 20 micron). The mobile phase was 60% of ethanol in hexanes at a flow rate of 35 mL/min. f] [1, 4] -11-oxo-N-(pyridin-3-ylmethyl)-10,11-dihydrodibenzo[b,f] [1, 4] thiazepine-8carboxamide 5-(R)-oxide ((R)-63). Separation of enantiomers via chiral HPLC: Analytical analysis was performed on a CHIRALPAK ® IA column (4.6 × 250 mm, 5 micron). The mobile phase was 60% of ethanol in hexanes at a flow rate of 1.0 mL/min with a run time of 15 minutes. The sample was detected with a diode array detector (DAD) at 220 nm and 254 nm. Optical rotation was determined with an in-line polarimeter (PDR-Chiral). The first eluting peak: RT = 9.00 minutes; positive optical rotation. The second eluting peak: RT = 13.28 minutes; negative optical rotation. Preparative separation was performed on a CHIRALPAK ® IA column (5× 50 cm, 20 micron). The mobile phase was 60% of ethanol in hexanes at a flow rate of 35 mL/min. Fraction collection was triggered by UV absorbance (254 nm -11-oxo-N-(pyridin-3-ylmethyl)-10,11-dihydrodibenzo[b,f] [1, 4] -11-oxo-N-(2-(pyrrolidin-1-yl) ethyl)-10, 11dihydrodibenzo[b,f] [1, 4] thiazepine-8-carboxamide 5-(R)-oxide ((R)-64). Separation of enantiomers via chiral HPLC: Analytical analysis was performed on a CHIRALPAK ® IA column (4.6 × 250 mm, 5 micron). The mobile phase was 60% of ethanol in hexanes at a flow rate of 1.0 mL/min with a run time of 15 minutes. The sample was detected with a diode array detector (DAD) at 220 nm and 254 nm. Optical rotation was determined with an in-line polarimeter (PDR-Chiral). The first eluting peak: RT = 7.39 minutes; positive optical rotation. The second eluting peak: RT = 11.48 minutes; negative optical rotation. Preparative separation was performed on a CHIRALPAK ® IA column (5× 50 cm, 20 micron). The mobile phase was 60% of ethanol in hexanes at a flow rate of 35 mL/min with. Fraction collection was triggered by UV absorbance (254 nm -11-oxo-N-(2-(thiophen-2-yl)ethyl)-10,11dihydrodibenzo[b,f] [1, 4] thiazepine-8-carboxamide 5-(R)-oxide ((R)-65). Separation of enantiomers via chiral HPLC: Analytical analysis was performed on a CHIRALPAK ® IA column (4.6 × 250 mm, 5 micron). The mobile phase was 60% of ethanol in hexanes at a flow rate of 1.0 mL/min with a run time of 15 minutes. The sample was detected with a diode array detector (DAD) at 220 nm and 254 nm. Optical rotation was determined with an in-line polarimeter (PDR-Chiral). The first eluting peak: RT = 6.51 minutes; negative optical rotation. The second eluting peak: RT = 6.76 minutes; positive optical rotation. Preparative separation was performed on a CHIRALPAK ® IA column (5× 50 cm, 20 micron). The mobile phase was 60% of ethanol in hexanes at a flow rate of 35 mL/min. -11-oxo-N-(2-(thiophen-2-yl)ethyl)-10,11dihydrodibenzo[b,f] [1, 4] Scale up synthesis of 65. f][1, 4] thiazepine-8-carboxylic acid 5-(S)oxide ((S)-10b). The title enantiomerically pure compound was purified to > 98% purity using supercritical fluid chromatography (SFC) preparative systems at Lotus Separations, LLC (Princeton, NJ, USA). For preparative separation, an IC (2 x 15 cm) column was used with an eluent of 40% methanol (0.1% DEA)/CO 2 , 100 bar. Flow rate was 60 mL/min and detection wavelength was 220 nm. For analytical separation, an IC (15 x 0.46 cm) column was used with an eluent of 40% methanol/CO 2 , 100 bar. Flow rate was 3 mL/min and detection wavelengths were 220 and 280 nm. Retention time was 3.42 min. Retention time for R-configuration enantiomer was 2.40 min. The material was used directly in the next coupling reaction.
10
10-Ethyl-N-(4-methoxybenzyl)-N
N
4-
(R)-
10-Methyl
10- f][1, . A solution of 10-methyl-11-oxo-10,11dihydrodibenzo[b,f][1,4]thiazepine-8-carboxylic acid 5-(S)-oxide (100 mg, 0.332 mmol) in DMF (5.00 mL) was treated at room temperature with HATU (139 mg, 0.365 mmol) and diisopropylethylamine (0.174 mL, 0.996 mmol) followed by 2-(thiophen-2yl)ethanamine (84.0 mg, 0.664 mmol). The reaction mixture was stirred at room temperature for 3 h and poured into ice water. The white precipitate was filtered and dried to give a white solid, which was purified via silica gel chromatography using a gradient of 10-100% of EtOAc in hexanes to give 118 mg (87%) of the title compound as a white solid. 1 16, 165.10, 147.66, 145.98, 141.75, 137.87, 137.02, 132.92, 131.69, 131.23, 128.20, 127.39, 126.51, 125.70, 124.57, 124.43, 121.05, 119.40, 41.55, 38.03, 29.49 ; LC-MS Retention Time: t 1 (Method 1) = 5.348 min; t 2 (Method 2) = 3.188 min; HRMS (ESI) m/z (M+H) + calcd. for C 21 H 19 (3) 8173 (2) -1365(2) 25(1) C(2) 4353 (3) 8955 (3) -1572(2) 29(1) C (3) 4859 (3) 9859 (2) -1511 (2) 27(1) C(4) 6062 (3) 9993 (2) -1265(2) 28(1) C(5) 6768 (3) 9198 (2) -1066(2) 23(1) C(6) 6285 (3) 8282 (2) -1106 (2) 17(1) C (7) 7013 (3) 7378 (2) -881(2) 21(1) C(8) 8379 (3) 7551 (3) -762 (3) 36(1) C(9) 6435 (2) 5977(2) 63(2) 18(1) C(10) 5981 (2) 5583 (2) 1004 (2) 17(1) C(11) 5546 (3) 4643 (2) 1022(2) 20(1) C(12) 5101 (2) 4255 (2) 1867(2) 20(1) C(13) 5104 (3) 4801 (2) 2681 (2) 17(1) C(14) 5571(2) 5731(2) 2696(2) 16(1) C(15) 5996 (2) 6124(2) 1846(2) 18(1) C(16) 6913 (3) 6491(2) 3911(2) 21(1) C(17) 7385 (3) 7484(2) 3652(2) 25(1) C(18) 4699 (3) 6591(2) 4075(2) 18(1) C(19) 3460 (3) 6195(2) 3866(2) 18(1) C(20) 2467 (3) 6809(2) 3894(2) 23(1) C(21) 1290 (3) 6465 (3) 3806 (2) 26(1) C(22) 1095 (3) 5492 (3) 3702 (2) 25(1) C(23) 2055 (3) 4854 (2) 3678 (2) 22(1) C(24) 3228 (3) 5210(2) 3754(2) 18(1) 1.231(4) N(1)- C(9) 1.345(4) N(1)-C (7) 1.465(4) N(1)-H(1A) 0.8800 N(2)- C(18) 1.359(4) N(2)- C(14) 1.434(4) N(2)- C(16) 1.490(4) C(1)-C(2) 1.379(5) C(1)- C(6) 1.396(4)
0.9500 C(6)-C (7) 1.528(4) C(7)-C(8) 1.534(5) C(7)-H(7A)
1.0000 C(8)-H(8A) 0.9800 C(8)-H(8B) 0.9800 C(8)-H(8C) 0.9800 C(9)-C(10) 1.512(4) C(10)- C(11) 1.396(4) C(10)- C(15) 1.401(4) C(11)- C(12) 1.390(4) C(11)-H(11A) 0.9500 C(12)- C(13) 1.370(4) C(12)-H(12A) 0.9500 C(13)- C(14) 1.396(4) C(14)- C(15) 1.391 (4) (3) 31 (1) 27 (1) 22 (1) -10(1) 3(1) -3(1) N(1)
25 (1) 14 (1) 13 (1) -1(1) 4(1) 4(1) N (2) 22 (1) 16 (1) 17 (1) -1(1) -2(1) -1(1) C (1) 25 (1) 25 (2) 25(2) 4(1) 5(1) -5(1) C(2) 20(1) 40(2) 26(2) 5(1) 2(1) 5(1) C (3) 39 (2) 27(2) 15(1) 3(1) 2(1) 18(1) C(4) 49 (2) 18 (1) 17 (1) 1(1) 2(1) -1(1) C (5) 27 (1) 22(2) 20(1) 2(1) -3(1) -3(1) C (6) 21 (1) 20 (1) 12(1) 2(1) 2(1) 2(1) C (7) 27 (2) 21 (1) 16(1) 4(1) 5(1) 6(1) C(8) 24 (2) 36 (2) 47(2) 17(2) 9(2) 10(1) C(9) 18 (1) 18 (1) 20 (1) -2(1) 1(1) 5(1) C (10) 18 (1) 16 (1) 16(1) 0(1) 0(1) 5(1) C(11) 23 (1) 18 (1) 18 (1) -4(1) 0(1) 1(1) C(12) 21 (1) 13 (1) 25 (1) 1(1) -1(1) 1(1) C(13) 19 (1) 15 (1) 18 (1) 2(1) 0(1) 2(1) C(14) 17 (1) 15 (1) 15 (1) -1(1) -1(1) 2(1) C(15) 20 (1) 14(1) 20(1) 0(1) -2(1) 1(1) C(16) 24(1) 20(1) 20(1) -2(1) -5(1) 0(1) C(17) 25(1) 26(2) 23(1) 0(1) -7(1) -4(1) C(18) 29 (2) 13(1) 13(1) 1(1) 1(1) 2(1) C(19) 24(1) 20(1) 10(1) -1(1) 2(1) 1(1) C(20) 30(2) 21(1) 17(1) -1(1) 3(1) 4(1) C(21) 25 (2) 35 (2) 17(1) -3(1) 2(1) 10(1) C(22) 21 (1) 39 (2) 15(1) -1(1) -3(1) -1(1) C(23) 26 (1) 26 (1) 13(1) 0(1) 1(1) -2(1) C(24) 21(1) 21(1) 11(1) 0(1) 0(1) 2(1) The single crystal X-ray diffraction studies were carried out on a Bruker Kappa APEX CCD diffractometer equipped with Cu K α radiation (λ = 1.5478). A 0.11 x 0.02 x 0.01 mm colorless needle was mounted on a Cryoloop with Paratone oil. Data were collected in a nitrogen gas stream at 100(2) K using φ and ω scans. Crystal-to-detector distance was 60 mm using variable exposure time (10 s -60 s) depending on θ with a scan width of 1.0°. Data collection was 93.3% complete to 68.00° in θ. A total of 5898 reflections were collected covering the indices, -37<=h<=30, -5<=k<=5, 0<=l<=21. 3145 reflections were found to be symmetry independent, with a R int of 0.0360. Indexing and unit cell refinement indicated a C-centered, monoclinic lattice. The space group was found to be C2. The data were integrated using the Bruker SAINT software program and scaled using the SADABS software program. Solution by direct methods (SHELXS) produced a complete phasing model consistent with the proposed structure. All nonhydrogen atoms were refined anisotropically by full-matrix least-squares (SHELXL-97). All hydrogen atoms were placed using a riding model. Their positions were constrained relative to their parent atom using the appropriate HFIX command in SHELXL-97. Crystallographic data for 65 are summarized in Table S6 -S12. (12) 44(1) C(4) 1713(2) -1035(10) 6594 (3) 40 (1) C (21) 5818 (4) -9760(30) 14324 (7) 44 (1) C(5) 1886(2) 119 (10) 7404 (3) 35 (1) S(2B) 5439(2) -8275 (11) 13844 (3) 44(1) C (6) 2294(1) 2076 (9) 7784(2) 26(1) S(2D) 6139(2) -8001 (12) 13559 (3) 44(1) C (7) 2456(2) 3277 (9) 8656 (3) 33 (1) O(3B) 4859(2) -4081 (12) 10366 (3) 30 (1) C(8) 3087(2) 4527(12) 10161(3) 48(1) N(2B) 4517 (3) -3746 (14) 11173 (5) 30(1) C(9) 3371 (2) 2205 (9) 9285(2) 28(1) C(15B) 4544 (3) -3031 (19) 10497 (5) 30(1) C(10) 3453 (2) 2892 (8) 8635 (2) 26(1) C(16B) 4857 (3) -5861(18) 11808(5) 30(1) C(11) 3844 (2) 1740(11) 8615 (3) 37(1) C(17B) 5339 (3) -4650 (20) 12597 (5) 30(1) C(12) 4175(2) -155 (11) 9269 (3) 48(1) C(18B) 5623(11) -6760 (40) 13287(15) 44(1) C (13) 4118(2) -845 (9) 9938 (3) 48(1) C(19B) 6139(2) -8001 (12) 13559 (3) 44(1) C(14) 3721 (2) 400 (10) 9952 (2) 38(1) C(19D) 5439(2) -8275 (11) 13844 (3) 44(1) S(2) 5404(2) -7636(11) 13592 (3) (2) 23(2) 5(1) 14(2) -5(2) O(2) 50(2) 51(2) 48(2) -5(2) 40(2) -4(2) N(1) 37(2) 31(2) 23(2) -6(1) 18(2) -8(2) C(1) 27(2) 21(2) 24(2) 5(1) 10(2) 7(2) C(2) 34(2) 29(2) 25(2) 2(2) 14(2) 9(2) C (3) 39 (2) 32 (3) 23 (2) -2(2) 8(2) 6(2) C(4) 31(2) 31(2) 41 (3) -3(2) 10(2) -4(2) C(5) 31(2) 31(2) 39(2) 2(2) 17(2) -1(2) C (6) 25 (2) 23 (2) 27(2) -1(2) 13(2) 6(2) C (7) 45 (2) 27 (2) 35 (2) 3 (2) 27(2) -2(2) C(8) 61 (3) 63 (3) 39 (2) -25(2) 39(2) -33 (3) C(9) 32 (2) 22(2) 20(2) 1(2) 10(2) -3(2) C (10) 29 (2) 19(2) 20(2) 0(1) 7(2) 2(2) C(11) 34(2) 39(2) 34(2) -9(2) 16(2) 4(2) C(12) 29 (2) 44 (3) 45 (3) -9(2) 4(2) 11(2) C(13) 33 (2) 17 (2) 39 (3) 2(2) -13(2) -4(2) C(14) 41 (2) 23(2) 21(2) 4(2) 0(2) -11(2) S(2) 35(1) 45(1) 39(1) 6(1) 12(1) 7(1) S(2C) 35(1) 45(1) 39(1) 6(1) 12(1) 7(1) O (3) 30(1) 23(1) 27(1) 3(1) 9(1) 1(1) N(2) 30(1) 23(1) 27(1) 3(1) 9(1) 1(1) C(15) 30(1) 23(1) 27(1) 3(1) 9(1) 1(1) C(16) 30(1) 23(1) 27(1) 3(1) 9(1) 1(1) C(17) 30 (1) 23 (1) 27 (1) 3(1) 9(1) 1(1) C(18) 35 (1) 45(1) 39(1) 6(1) 12(1) 7(1) C(19) 35 (1) 45(1) 39(1) 6(1) 12(1) 7(1) C(19C) 35 (1) 45(1) 39(1) 6(1) 12(1) 7(1) C(20) 35 (1) 45(1) 39(1) 6(1) 12(1) 7(1) C(21) 35 (1) 45(1) 39(1) 6(1) 12(1) 7(1) S(2B) 35(1) 45(1) 39(1) 6(1) 12(1) 7(1) S(2D) 35(1) 45(1) 39(1) 6(1) 12(1) 7(1) O(3B) 30(1) 23(1) 27(1) 3(1) 9(1) 1(1) N(2B) 30(1) 23(1) 27(1) 3(1) 9(1) 1(1) C(15B) 30(1) 23(1) 27(1) 3(1) 9(1) 1(1) C(16B) 30(1) 23(1) 27(1) 3(1) 9(1) 1(1) C(17B) 30(1) 23(1) 27(1) 3(1) 9(1) 1(1) C(18B) 35(1) 45(1) 39(1) 6(1) 12(1) 7(1) C(19B) 35(1) 45(1) 39(1) 6(1) 12(1) 7(1) C(19D) 35(1) 45(1) 39(1) 6(1) 12(1) 7(1) C(20B) 35(1) 45(1) 39(1) 6(1) 12(1) 7(1) C(21B) 35(1) 45(1) 39(1) 6(1) 12(1) 7(1) Binding curves for D 2 and D 3 displacement assay Figure S3 . Binding curves for D 2 and D 3 displacement assay. In house data for reference compounds Table S15. In house data for reference compounds. Reported values represent mean +/-SEM from experiments run in triplicate. Results with an asterisk (*) indicate values of a single 12-point concentration-response titration, and errors in these values are expected to be similar to other samples tested in triplicate, as they were run under identical conditions on the same day.
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